Current Challenges in Cancer Treatment

Zugazagoitia, Jon; Guedes, Cristiano; Ponce, Santiago; Ferrer, Irene; Molina-Pinelo, Sonia; Paz‐Ares, Luis

doi:10.1016/j.clinthera.2016.03.026

Cited by 685 publications

(436 citation statements)

References 78 publications

Supporting

Mentioning

427

Contrasting

Unclassified

Order By: Relevance

“…Molecular targeted therapy is an advanced treatment option in cancer therapy that has become a major focus in cancer research because of fewer side effects and higher efficacy than standard chemotherapy agents [38]. Several different molecules can be considered targets for therapy, such as members of the signal transduction pathway; however, clinical tests have determined that drug resistance can be achieved when the pathway is altered [39–41].…”

Section: Mechanisms Of Cancer Cell Drug Resistancementioning

confidence: 99%

Long non-coding RNAs in anti-cancer drug resistance

et al. 2016

View full text Add to dashboard Cite

Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly responsible for the failure of clinical treatment. The mechanism of drug resistance is complicated because of interaction among various factors including drug efflux, DNA damage repair, apoptosis and targets mutation. Long non-coding RNAs (lncRNAs) have been a focus of research in the field of bioscience, and the latest studies have revealed that lncRNAs play essential roles in drug resistance in breast cancer, gastric cancer and lung cancer, et al. Dysregulation of multiple targets and pathways by lncRNAs results in the occurrence of chemoresistance. In this review, we will discuss the mechanisms underlying lncRNA-mediated resistance to chemotherapy and the therapeutic potential of lncRNAs in future cancer treatment.

show abstract

Section: Mechanisms Of Cancer Cell Drug Resistancementioning

confidence: 99%

Long non-coding RNAs in anti-cancer drug resistance

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Current conventional chemotherapy has various limitations (i.e., severe adverse effects and resistance to treatment) (2); thus the identification of novel effective and selective antitumor compounds is mandatory. An excellent analysis of the current challenges and future objectives in the treatment of cancer reported that the continuously growing knowledge of molecular and cellular tumor biology has revolutionized cancer treatment towards: i) the technological improvement of tumor molecular profiling; and ii) the discovery of predictive molecular targets (3). …”

Section: Introductionmentioning

confidence: 99%

Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity

Mioc

Şoica

Bercean³

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

The extensive biochemical research of multiple types of cancer has revealed important enzymatic signaling pathways responsible for tumor occurrence and progression, thus compelling the need for the discovery of new means with which to block these signaling cascades. The phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway, which plays an important role in maintaining relevant cellular functions, exhibits various alterations in common human cancers, thus representing a suitable target in cancer treatment. Molecules bearing the 1,2,4-triazole moiety are known to possess multiple biological activities, including anticancer activity. The current study used molecular docking in the design of 5-mercapto-1,2,4-triazole derivatives with antiproliferative activity targeting the PI3K/AKT pathway. Three structures emerged as the result of this method, which indicated for these a highly favorable accommodation within the active binding site of PI3K protein, thus acting as potential PI3K inhibitors, and hence interfering with the above-mentioned pathway. The molecules were synthesized and their chemical structure was confirmed. The antiproliferative activity of these compounds was tested on 4 cancer cell lines (A375, B164A5, MDA-MB-231 and A549) and on normal human keratinocytes (HaCaT) by in vitro alamarBlue assay. The 3 compounds revealed antitumor activity against the breast cancer cell line (MDA-MB-231) and reduced toxicity on the normal cell line. The antibacterial activity of the compounds was also tested in vitro on Gram-positive and Gram-negative bacterial strains, revealing moderate activity.

show abstract

“…It is reported that 4,292,000 new cancer cases and 2,814,000 cancer deaths are predicted to occur in China in 2015 [1] and 1,688,780 new cancer cases and 600,920 cancer deaths will occur in United States in 2017 [2]. Despite current advances in surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy, cancer remains a leading cause of death and constitutes an enormous burden worldwide [3, 4]. One of the reasons affecting the tumor prognosis was lacking of effective early diagnostic method before progression and effective prognostic indicator for guiding the clinical treatment.…”

Section: Introductionmentioning

confidence: 99%

ZFAS1: a novel tumor-related long non-coding RNA

Dong

Zhao

et al. 2018

Cancer Cell Int

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNA) are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that lncRNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. In addition, aberrant expression of lncRNAs has been discovered in human tumors, where they function as either oncogenes or tumor suppressor genes. Among numerous lncRNAs, we focus on ZNFX1 antisense RNA 1 (ZFAS1), a well-known lncRNA that is aberrant overexpression in various tumors, including melanoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and Hepatocellular carcinoma, in which it functions as oncogene. In contrast, ZFAS1 is downregulated in breast cancer, which may function as tumor suppressor gene. In this review, we provide an overview of current evidence concerning the role and potential clinical utilities of ZFAS1 in human cancers.

show abstract

Current Challenges in Cancer Treatment

Cited by 685 publications

References 78 publications

Long non-coding RNAs in anti-cancer drug resistance

Long non-coding RNAs in anti-cancer drug resistance

Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity

ZFAS1: a novel tumor-related long non-coding RNA

Contact Info

Product

Resources

About